Linda Hertz Group

My Medical Device Sales Career

How To Evaluate a Potential Employer: Axogen Inc. Case Study

Some of you who are in my Group are learning how to follow companies and evaluate that companies financial numbers and new press releases to judge if a company is one you want to work for or perhaps even a company you want to remain if you are currently an employee.  If they are publicly held company it is very easy to follow your company of interest.

Our last company that we began this process with was with Intuitive Surgical and I continue to update that with significant news releases or investor news.

Today, we will begin this process with a young company who just came on the stock exchange this year, Axogen Incorporated.  Again, this is just a way for me to show people how they can quickly study a company and stay on top of current news.  I will be tracking major events or financial news for the next 6 months as a case in study for Axogen Inc.

  1. Their Website:
  2. Yahoo Financial Page:

The no. 2 above is the key and most important to use as a resource.  You can listen or read their earning report each quarter where the powers to be must share their numbers and their go forward estimates of declines or increases in their business and why.  Off the Yahoo Link for Axogen you can find the following:

Not complicated, but few do this with their current employer or future employers they are interviewing with and it results in the calls I will often get, "Gosh, I just started with this company last year and they are going under!" or "I hired in 6 months ago and now I am being let go because of their sales not hitting the mark."  Don't be one of them! Do your homework!

If you take on a young company, than evaluate the risks and if they are not yet on the stock exchange (as many are not), then it is time to ask the tough questions that these financial reports and earning reports address; what's the burn rate of the funds or funding available before a possible burn out against current sales and earnings (if they have any sales).  Believe me, start ups always tend to underestimate the amount of money they need before they can get into the black (that's profit!).

I hope this helps you conduct your own company case study as we begin with Axogen Inc.

Disclosure: This is a new contracted company for my firm

©Linda Hertz, All Rights Reserved  

SEE All Our Career Blogs.

By Linda Hertz why not invite me to your LinkedIn? View my profile and let's connect today! 

View Linda Hertz's profile on LinkedIn

See ALL Our Career Resources at No Charge Today!  Linda Hertz Group: VIEW ALL USA MEDICAL JOBS!

Views: 692

Tags: Understanding Company Strength


You need to be a member of Linda Hertz Group to add comments!

Join Linda Hertz Group

Comment by Linda Hertz on March 31, 2014 at 5:17pm

March 31, 2014 Income Statement

Comment by Linda Hertz on March 7, 2014 at 5:39pm

AxoGen's CEO Discusses Q4 2013 Results - Earnings Call Transcript

Comment by Linda Hertz on January 24, 2014 at 9:50am

AxoGen, Inc. Gives Presentation on Nerve Repair Science at International Conference

Comment by Linda Hertz on January 17, 2014 at 11:16am

AxoGen's Avance(R) Nerve Graft Recipient to Ride in 2014 Rose Parade aboard Donate Life's 'Light Up the World' Float on New Year's Day

Also VERY Visible exposure at the Rose Bowl this year on one Veterans Story of their technology saving his leg:

Fox News:

Comment by Linda Hertz on January 17, 2014 at 11:14am

Congrats on their new 2014 Award!

AxoGen Receives Product Innovation Leadership Award from Frost & Sullivan
Frost & Sullivan Innovation Award Highlights Significance of Avance® Nerve Graft
for Peripheral Nerve Repair
ALACHUA, FL – January 6, 2014 – AxoGen, Inc. (NASDAQ: AXGN), the only regenerative medicine company completely focused on peripheral nerve repair, has been awarded the 2014 North American New Product Innovation Leadership Award for Peripheral Nerve Repair by the preeminent global research organization, Frost & Sullivan. The award is based on the findings of Frost & Sullivan’s Best Practices Research Team which studied the nearly one million peripheral nerve injury repair procedures performed every year in the United States and recognized AxoGen for developing and commercializing the Avance® Nerve Graft.
The accolade was announced in a press release issued by Frost & Sullivan earlier today, highlighting several unique properties and benefits of AxoGen’s Avance® Nerve Graft and its significance in the peripheral nerve graft repair market. Frost & Sullivan used five criteria to benchmark Avance® Nerve Graft against key competitors:
 Innovative Element of the Product
 Leverage of Leading-Edge Technologies in Product
 Value Added Features/Benefits
 Increased Customer ROI
 Customer Acquisition/Penetration Potential
Each year, Frost & Sullivan presents the New Product Innovation Leadership Award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The company’s analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
“The Frost & Sullivan award is a major achievement for AxoGen given the independent research methodologies used by their organization to evaluate surgical repair options in the peripheral nerve market,” said Karen Zaderej, CEO of AxoGen. “It is our goal to improve the quality of life for patients with peripheral nerve injuries and it is an honor for AxoGen to receive this endorsement of the innovative impact of the Avance® Nerve Graft for nerve repair. “
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community for more than 50 years.
About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a regenerative medicine company based in Alachua, Florida. Founded in 2002, AxoGen is the only company to completely focus on peripheral nerve repair. AxoGen’s portfolio of products are available in the United States, Canada and several European countries and includes Avance® Nerve Graft, the only off-the-shelf commercially
available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.
Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, West Lafayette, Indiana, and are distributed exclusively by AxoGen. AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen's principal executive office and operations are located in Alachua, FL.
To receive email alerts directly from AxoGen, please click here
Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product commercialization and marketing efforts for its portfolio of peripheral nerve repair products, Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector, product development, financial performance, sales growth, product adoption, market awareness of our products, data validation and the intent to list on a national securities exchange. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.
AxoGen, Inc.
Greg Freitag, Chief Financial Officer

Comment by Linda Hertz on November 13, 2013 at 1:06pm

I think this Nov. 8th Seeking Alpha article is interesting in our continued look at this company

AxoGen Remains A Strong Investment After Positive Third Quarter Results, Link:


Our Job Portal Link:



  • Add Photos
  • View All

Our Open Jobs by State

VIEW ALL OUR OPEN JOBS BY STATE/CITY with confidential direct application.

Linda Twitters Daily!

Yes We Do!

We Tweet daily all our jobs, recruiting activity and career articles and more:

Follow us at:

Linda Hertz Twitter


  • Add Videos
  • View All

© 2020   Created by Linda Hertz.   Powered by

Badges  |  Report an Issue  |  Terms of Service